- Home
- ATLC vs ABUS Comparison
ATLC vs ABUS Comparison
Compare ATLC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- ABUS
- Stock Information
- Founded
- ATLC 1996
- ABUS 2005
- Country
- ATLC United States
- ABUS United States
- Employees
- ATLC N/A
- ABUS N/A
- Industry
- ATLC Finance: Consumer Services
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- ATLC Finance
- ABUS Health Care
- Exchange
- ATLC Nasdaq
- ABUS Nasdaq
- Market Cap
- ATLC 732.1M
- ABUS 672.1M
- IPO Year
- ATLC 1999
- ABUS N/A
- Fundamental
- Price
- ATLC $49.05
- ABUS $3.36
- Analyst Decision
- ATLC Strong Buy
- ABUS Strong Buy
- Analyst Count
- ATLC 5
- ABUS 4
- Target Price
- ATLC $62.00
- ABUS $5.50
- AVG Volume (30 Days)
- ATLC 47.2K
- ABUS 843.8K
- Earning Date
- ATLC 05-08-2025
- ABUS 05-14-2025
- Dividend Yield
- ATLC N/A
- ABUS N/A
- EPS Growth
- ATLC 21.75
- ABUS N/A
- EPS
- ATLC 5.17
- ABUS N/A
- Revenue
- ATLC $424,877,000.00
- ABUS $6,403,000.00
- Revenue This Year
- ATLC $270.55
- ABUS $14.57
- Revenue Next Year
- ATLC $11.94
- ABUS $15.84
- P/E Ratio
- ATLC $9.48
- ABUS N/A
- Revenue Growth
- ATLC 17.71
- ABUS N/A
- 52 Week Low
- ATLC $25.14
- ABUS $2.71
- 52 Week High
- ATLC $64.70
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- ATLC 41.02
- ABUS 53.55
- Support Level
- ATLC $48.36
- ABUS $3.04
- Resistance Level
- ATLC $49.80
- ABUS $3.54
- Average True Range (ATR)
- ATLC 1.90
- ABUS 0.14
- MACD
- ATLC -0.55
- ABUS 0.02
- Stochastic Oscillator
- ATLC 23.48
- ABUS 70.00
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.